Scilex Holding Co
SCLX29.080USD
+3.420+13.33%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
159.87MMarket Cap
LossP/E TTM
More Details of Scilex Holding Co Company
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
Company Info
Ticker SymbolSCLX
Company nameScilex Holding Co
IPO dateJan 11, 2021
CEODr. Henry H. Ji, Ph.D.
Number of employees115
Security typeOrdinary Share
Fiscal year-endJan 11
Address960 San Antonio Road
CityPALO ALTO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94303
Phone16505164310
Websitehttps://www.scilexholding.com/
Ticker SymbolSCLX
IPO dateJan 11, 2021
CEODr. Henry H. Ji, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Henry H. Ji, Ph.D.
Dr. Henry H. Ji, Ph.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
19.45K
--
Mr. Jaisim Shah
Mr. Jaisim Shah
Director
Director
8.43K
--
Dr. Jay Chun, M.D., Ph.D.
Dr. Jay Chun, M.D., Ph.D.
Independent Director
Independent Director
3.21K
--
Dr. Yue Alexander Wu, Ph.D.
Dr. Yue Alexander Wu, Ph.D.
Independent Director
Independent Director
714.00
--
Mr. Dorman Followwill
Mr. Dorman Followwill
Independent Director
Independent Director
65.00
--
Dr. Annu Navani, M.D.
Dr. Annu Navani, M.D.
Independent Director
Independent Director
--
--
Mr. Stephen Ma
Mr. Stephen Ma
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Henry H. Ji, Ph.D.
Dr. Henry H. Ji, Ph.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
19.45K
--
Mr. Jaisim Shah
Mr. Jaisim Shah
Director
Director
8.43K
--
Dr. Jay Chun, M.D., Ph.D.
Dr. Jay Chun, M.D., Ph.D.
Independent Director
Independent Director
3.21K
--
Dr. Yue Alexander Wu, Ph.D.
Dr. Yue Alexander Wu, Ph.D.
Independent Director
Independent Director
714.00
--
Mr. Dorman Followwill
Mr. Dorman Followwill
Independent Director
Independent Director
65.00
--
Dr. Annu Navani, M.D.
Dr. Annu Navani, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
56.59M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Aug 28
Updated: Thu, Aug 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
SCLX Stock Acquisition JV LLC
20.96%
The Vanguard Group, Inc.
4.23%
BlackRock Institutional Trust Company, N.A.
1.70%
Geode Capital Management, L.L.C.
0.89%
Ji (Henry H)
0.28%
Other
71.93%
Shareholders
Shareholders
Proportion
SCLX Stock Acquisition JV LLC
20.96%
The Vanguard Group, Inc.
4.23%
BlackRock Institutional Trust Company, N.A.
1.70%
Geode Capital Management, L.L.C.
0.89%
Ji (Henry H)
0.28%
Other
71.93%
Shareholder Types
Shareholders
Proportion
Corporation
20.96%
Investment Advisor
6.50%
Investment Advisor/Hedge Fund
1.53%
Individual Investor
0.47%
Research Firm
0.42%
Hedge Fund
0.38%
Sovereign Wealth Fund
0.20%
Bank and Trust
0.11%
Other
69.43%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
243
2.86M
41.63%
-723.36K
2025Q1
252
1.46M
45.15%
-3.55M
2024Q4
251
112.59M
54.83%
-47.55M
2024Q3
250
97.43M
52.53%
-74.03M
2024Q2
251
103.17M
56.73%
-57.85M
2024Q1
249
91.86M
57.21%
-68.00M
2023Q4
233
89.70M
66.12%
-73.38M
2023Q3
225
92.65M
59.63%
-2.57M
2023Q2
215
84.74M
56.99%
-3.00M
2023Q1
187
79.37M
78.26%
-5.74M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SCLX Stock Acquisition JV LLC
1.46M
20.98%
+1.42M
+3399.97%
May 01, 2025
The Vanguard Group, Inc.
168.51K
2.42%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
161.07K
2.32%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
46.00K
0.66%
+10.32K
+28.93%
Mar 31, 2025
Ji (Henry H)
19.45K
0.28%
+18.90K
+3398.56%
May 01, 2025
Rafferty Asset Management LLC
17.72K
0.25%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
20.53K
0.3%
+18.12K
+751.56%
Mar 31, 2025
Morgan Stanley & Co. LLC
9.48K
0.14%
-4.93K
-34.20%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
13.65K
0.2%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
